Can ICER bring cost-effectiveness to drug prices?

Q4 Medicine

Managed Care Pub Date : 2019-06-01

Lola Butcher

引用次数: 0

Abstract

Insurers and some drug manufacturers are turning to the Institute for Clinical and Economic Review (ICER) as the arbiter of drug prices, especially as prices soar and value is sought. But questions persist about the cost-effectiveness calculations of the Boston not-for-profit and its dependence on QALYs.

本刊更多论文

ICER能给药品价格带来成本效益吗?

保险公司和一些药品制造商正把临床和经济评论研究所(ICER)作为药品价格的仲裁者，尤其是在价格飙升和追求价值的情况下。但对于这家波士顿非营利机构的成本效益计算及其对质量评估年的依赖，问题依然存在。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊